$PBH (Prestige Brands Holdings, Inc.)

$PBH {{ '2016-05-12T13:01:20+0000' | timeago}} • Webcast

$PBH, which markets medical and healthcare products like Clear Eyes and The Doctor's, said that in 4Q16, sales growth was helped by consumption gains in core OTC brands. The company said that the Dentek Holdings acquisition was completed in February 2016 and the integration is expected to complete by the end of June.

$CL {{ '2017-07-21T18:17:33+0000' | timeago}} • Webcast

$CL expects net sales to be up low-single digits for the year with a slight negative impact from foreign exchange. The FMCG giant, as it posted 2Q17 results, now sees organic sales growth will be in the low single digits.

$GSK {{ '2017-07-21T15:28:58+0000' | timeago}} • Announcement

$GSK and $INVA announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta in patients with controlled asthma on an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA).

$MRK {{ '2017-07-21T15:21:07+0000' | timeago}} • Announcement

President Donald Trump announced that pharma giants $MRK and $PFE are collaborating with Gorilla Glass manufacturer Corning ($GLW) for manufacturing a new glass (Valor Glass), which is superior and reliable for the delivery of injectable drugs. Corning is planning to initially invest $500MM creating 1,000 jobs at 3 facilities in US.

$CL {{ '2017-07-21T12:30:24+0000' | timeago}} • Infographic

$CL Colgate-Palmolive Co Earnings AlphaGraphics: Q2 2017 highlights

$CL {{ '2017-07-21T11:47:23+0000' | timeago}} • Announcement

In 2Q17, $CL's North America net sales fell 3.5% and Latin America net sales rose 7.0%. The FMCG giant's CEO Ian Cook said, "we continue to expect low-single-digit net sales increase for 2017, and given our slower than expected first half, we are now planning for low-single-digit organic sales growth for 2017."

$CL {{ '2017-07-21T11:44:42+0000' | timeago}} • Announcement

Worldwide reported net sales of $CL slipped 0.5% to $3.83Bil in 2Q17 with global unit volume falling 1%. Organic sales were even with the year ago period, and net income slumped to $524MM and $0.59 per diluted share from last year's $600MM and $0.67 per diluted share.

$JNJ {{ '2017-07-18T19:50:54+0000' | timeago}} • Webcast

$JNJ expects that the growth acceleration in the back half of 2017 will create some momentum going into 2018, as the majority of growth acceleration in both Hospital Medical Devices and Consumer have to do with new product launches. However, the company said it is not prepared to talk about guidance.

$JNJ {{ '2017-07-18T19:30:46+0000' | timeago}} • Webcast

$JNJ CEO Alex Gorsky said during the conference call, "We remain very optimistic about Pharma in the second half of the year and we continue to see really strong uptake both with DARZALEX and the various multiple myeloma indications earlier utilization."

$JNJ {{ '2017-07-18T18:58:31+0000' | timeago}} • Webcast

$JNJ said it has a pipeline of more than 10 new blockbuster products to launch or file for regulatory approval in the next five years, each with greater than $1Bil in peak year sales potential.

$JNJ {{ '2017-07-18T11:59:48+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphics: Q2 2017 highlights

$JNJ {{ '2017-07-18T11:26:59+0000' | timeago}} • Announcement

Medical Devices segment was the top performer for $JNJ in 2Q17, with a growth of 4.9%. While Consumer segment added to this with a 1.7% growth, Pharmaceutical segment edged down 0.2%.

$JNJ {{ '2017-07-18T11:19:55+0000' | timeago}} • Announcement

$JNJ CEO Alex Gorsky said, "Our pharmaceutical pipeline continued its strong momentum with the approval of TREMFYA as well as the submission and approval of several key line extensions. We are optimistic that the investments we are making will accelerate our sales growth in the second half of this year."

$JNJ {{ '2017-07-18T11:14:25+0000' | timeago}} • Announcement

$JNJ, which recently acquired Actelion Ltd for $30Bil, raised its sales guidance for FY17 to $75.8-76.1Bil. Additionally, the New Brunswick, NJ - based company raised its adjusted earnings guidance for the same period to $7.12-7.22 per share.

$JNJ {{ '2017-07-18T11:08:14+0000' | timeago}} • Announcement

Pharmaceutical giant $JNJ reported growth in sales and adjusted EPS in 2Q17. While sales increased 2% to $18.8Bil riding on International sales growth of 2.3%, adjusted EPS stood at $1.83, representing an increase of 3.1%. On a GAAP basis, net earnings were down to $3.8Bil, or $1.40 per share, compared to $4Bil, or $1.43 per share, a year ago.

$PG {{ '2017-07-17T22:15:27+0000' | timeago}} • Announcement

$PG said it continues to execute on bold productivity initiatives and plans to deliver up to $10Bil over the next five fiscal years. The company recently announced a 3% increase to its quarterly dividend, and expects total dividend payments to shareholders of more than $7Bil in FY17.

$JNJ {{ '2017-07-17T15:58:16+0000' | timeago}} • Announcement

$JNJ has declared a cash dividend for 3Q17 of $0.84 per share on its common stock. The dividend is payable on September 12, 2017 to shareholders of record as on August 29, 2017. The ex-dividend date is August 25, 2017.

$VRX {{ '2017-07-17T14:04:54+0000' | timeago}} • Announcement

$VRX has entered into an agreement to sell its Obagi Medical Products business for $190MM in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. The transaction is expected to close in second half of 2017. $VRX intends to use the proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility.

$CHD {{ '2017-07-17T11:58:51+0000' | timeago}} • Announcement

$CHD has agreed to acquire water-jet technology company Water Pik, Inc. from MidOcean Partners for approx $1Bil in cash. The acquisition is expected to be neutral to its 2017 EPS. The transaction, which will be financed with debt, is expected to close in the third quarter.

$PFE {{ '2017-07-13T12:13:49+0000' | timeago}} • Announcement

The FDA has accepted $PFE's filing of supplemental New Drug Application (sNDA) for XELJANZ (tofacitinib citrate), an investigational oral treatment for adult patients with moderately to severely active ulcerative colitis. The FDA has provided an anticipated Prescription Drug User Fee Act action date in March 2018 for the sNDA.

$PFE {{ '2017-07-12T11:41:14+0000' | timeago}} • Announcement

$PFE said the FDA's Oncologic Drug Advisory Committee (ODAC) voted that the results of ALFA-0701 demonstrated a favorable risk benefit profile for Mylotarg on days 1, 4 and 7 added to chemotherapy for patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML).

Recent Transcripts

CL (Colgate-Palmolive Co.)
Friday, July 21 2017 - 3:00pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, May 11 2017 - 12:30pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, May 11 2017 - 12:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
ACET (Aceto Corp.)
Friday, May 5 2017 - 1:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
CHD (Church & Dwight Co. Inc.)
Thursday, May 4 2017 - 2:00pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
CLX (The Clorox Company)
Wednesday, May 3 2017 - 5:30pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm
CL (Colgate-Palmolive Co.)
Friday, April 28 2017 - 3:00pm
GSK (GlaxoSmithKline plc)
Wednesday, April 26 2017 - 1:00pm
MDCO (The Medicines Company)
Wednesday, April 26 2017 - 12:30pm
PG (The Procter & Gamble Company)
Wednesday, April 26 2017 - 12:30pm
JNJ (Johnson & Johnson)
Tuesday, April 18 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm
MDCO (The Medicines Company)
Tuesday, February 28 2017 - 1:30pm

AlphaGraphics you may like